# Non Alcoholic Fatty Liver Disease Market

> Non-Alcoholic Fatty Liver Disease Market Research Report By Diagnosis Method (Ultrasound, CT Scan, MRI, Liver Biopsy), By Treatment Type (Lifestyle Changes, Medications, Surgical Procedures, Nutritional Supplements), By Patient Demographics (Adults, Children, Elderly), By Complication Type (Fibrosis, Cirrhosis, Hepatocellular Carcinoma) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Growth & Industry Forecast 2025 To 2035

- **Forecast Period:** 2026-2035
- **CAGR:** 16.75%
- **2025:** USD 18.62 Billion
- **2035:** USD 87.94 Billion
- **Key Players:** Madrigal Pharmaceuticals, Novo Nordisk, Eli Lilly, Intercept Pharmaceuticals, Gilead Sciences, Novartis, Boehringer Ingelheim, AstraZeneca

**Report ID:** MRFR/HC/40511-HCR · **Pages:** 100 · **Author:** Nidhi Mandole & Satyendra Maurya · **Last Updated:** September 17, 2026

**URL:** https://www.marketresearchfuture.com/reports/non-alcoholic-fatty-liver-disease-market-42175

---

## Market Summary

## Non Alcoholic Fatty Liver Disease Market Summary

The Non-Alcoholic Fatty Liver Disease NAFLD Market was valued at USD 18.62 billion in 2025 and is projected to open the forecast window at USD 21.74 billion in 2026 before reaching USD 87.94 billion by 2035, expanding at a 16.75% CAGR across 2026–2035. Two catalysts anchor that trajectory. The U.S. Food and Drug Administration's accelerated approval of resmetirom in March 2024 converted a diagnosis of exclusion into a treatable indication with a defined reimbursement path [1]. Alongside it, the European Medicines Agency's 2023 reflection paper on non-invasive endpoints lowered the evidentiary burden for sponsors running late-stage histology trials [2]. Together, they reset sponsor economics for the Non-Alcoholic Fatty Liver Disease NAFLD Market.

Diagnostics are undergoing a sharper transformation. Percutaneous liver biopsy — invasive, costly, and prone to sampling error — is being displaced by vibration-controlled transient elastography, MRI-PDFF, and serum panels such as ELF and FIB-4. The National Institutes of Health committed roughly USD 240 million across NIDDK metabolic-liver programs in FY2024, much of it directed at validating non-invasive staging [3]. Payer acceptance followed: CMS extended national coverage for elastography in primary-care screening pathways during 2024, widening the diagnosed pool that any therapy must ultimately serve.

North America leads the Non-Alcoholic Fatty Liver Disease NAFLD Market with 41.6% revenue share in 2025, supported by early resmetirom uptake and dense hepatology infrastructure. Asia-Pacific grows fastest at an 18.02% CAGR through 2035 as urban obesity and type 2 diabetes prevalence climb across China and India. Europe ranks second at 26.4% share, propelled by EASL clinical-practice guidelines that formalized risk stratification in primary care. The decade ahead will be defined less by whether therapies work and more by how quickly health systems can find the patients who need them.

## Key Report Takeaways

### • By Drug Class

- Antioxidants held 30.4% revenue share in 2025, reflecting entrenched generic availability and physician familiarity across the Non-Alcoholic Fatty Liver Disease NAFLD Market
- FXR receptor agonists post the fastest expansion at a 17.94% CAGR through 2035 as nuclear-receptor modulation validates disease-modifying claims
- Fibrosis treatment agents are forecast to reach USD 14.86 billion by 2035 as advanced-stage patients enter treatment

### • By Distribution Channel

- Hospital pharmacies commanded 50.8% of 2025 revenue on the strength of specialist-initiated therapy and prior-authorization support
- Online pharmacies advanced at a 17.83% CAGR, the fastest channel in the Non-Alcoholic Fatty Liver Disease NAFLD Market
- Retail pharmacies contributed USD 4.09 billion in 2025, largely through comorbidity prescriptions

### • By Region

- North America dominated with 41.6% revenue share in 2025
- Asia-Pacific records the highest regional CAGR at 18.02% through 2035
- Europe generated USD 4.92 billion in 2025 across the Non-Alcoholic Fatty Liver Disease NAFLD Market

## Market Size and Forecast (2021–2035)

Market sizing draws on bottom-up reconstruction of branded and generic hepatology prescription volumes, triangulated against company-reported segment revenues, national prescription audits, and diagnosed-prevalence models built from NHANES, EASL registry data, and Asia-Pacific hospital cohorts. Historical years reflect actual reported sales; forecast years apply epidemiological progression rates, launch-curve assumptions for pipeline assets, and payer-coverage phasing by geography. Values are stated in USD Billion at constant 2025 exchange rates.

## Market Drivers

## Driver Impact Analysis

| Driver | ~% Impact on CAGR | Geographic Relevance | Impact Timeline | Ref |
| --- | --- | --- | --- | --- |
| First-in-class therapeutic approvals | 4.1 | Global | Short-term (≤2 yr) | [1] |
| Rising obesity and type 2 diabetes prevalence | 3.6 | Asia-Pacific, North America | Long-term (≥4 yr) | [7] |
| Non-invasive diagnostic adoption | 2.8 | North America, Europe | Medium-term (2–4 yr) | [3] |
| Accelerated regulatory pathways | 2.2 | US, EU, Japan | Short-term (≤2 yr) | [2] |
| Pharmaceutical M&A and licensing capital | 1.9 | Global | Medium-term (2–4 yr) | [8] |
| Reimbursement expansion for screening | 1.5 | North America, Europe | Medium-term (2–4 yr) | [9] |
| AI-enabled histology and risk scoring | 1.1 | Global | Long-term (≥4 yr) | [10] |

### First-in-Class Therapeutic Approvals

The regulatory framework for MASH with fibrosis was set by Resmetirom's rapid approval in March 2024, which used non-invasive surrogate endpoints that were verified against biopsies [1]. Within the first three quarters of launch, Madrigal reported net product revenue of about USD 180 million, which significantly exceeded expectations and indicated actual unmet demand. Additionally, approval freed payer infrastructure, such as hepatology referral coding, specialty-pharmacy routing, and prior-authorization criteria, which each new entry will inherit rather than develop.

### Rising Obesity and Type 2 Diabetes Prevalence

According to WHO projections, the number of adults who suffer from obesity has increased from 556 million in 2010 to 890 million now [7]. About 30% of adults worldwide suffer from hepatic steatosis due to metabolic inefficiency, and 5-7% go on to develop steatohepatitis. Endocrinology referral volumes are now the most trustworthy leading indication of treated-patient growth because type 2 diabetes increases the risk: patients with the disease have around twice the fibrosis-progression rate of non-diabetic cohorts.

### Non-Invasive Diagnostic Adoption

Biopsy captures roughly 1/50,000th of total liver volume, producing staging discordance in up to 33% of paired samples. Vibration-controlled transient elastography and MRI-PDFF removed that constraint, and NIDDK's FY2024 commitment of approximately USD 240 million toward metabolic liver research accelerated validation work [3]. Diagnosed prevalence in U.S. primary care rose an estimated 27% between 2022 and 2025 as FIB-4 screening entered routine metabolic panels, expanding the addressable treatment pool.

### Accelerated Regulatory Pathways

Regulators moved decisively once surrogate endpoints held up. The European Medicines Agency's 2023 reflection paper on NASH endpoints, followed by FDA's Subpart H framework application, cut median late-stage development timelines by an estimated 14 months [2]. Japan's PMDA introduced a parallel Sakigake designation route for metabolic hepatology assets in 2024. Compressed timelines lower capitalized development cost per asset, which explains the 2023–2025 surge in Phase III program starts.

### Pharmaceutical M&A and Licensing Capital

Deal flow confirms institutional conviction. Novo Nordisk's USD 1.1 billion acquisition of Akero-adjacent FGF-21 assets and Roche's USD 2.7 billion Carmot transaction both carried explicit hepatic-endpoint rationales [8]. Aggregate disclosed transaction value in metabolic liver disease exceeded USD 12 billion across 2023–2025. That capital funds Phase III enrollment at scale — the binding constraint on launch timing — and effectively guarantees a dense approval calendar between 2028 and 2032.

### Reimbursement Expansion for Screening

Payers historically declined to fund screening for a condition with no treatment. That logic inverted after 2024. CMS extended coverage for elastography within diabetes and [obesity management](https://www.marketresearchfuture.com/reports/obesity-management-market-2690) pathways, and eight European national systems added FIB-4 to standard metabolic panels [9]. Screening cost per case identified fell to roughly USD 310, comfortably inside cost-effectiveness thresholds, and each newly identified fibrotic patient represents multi-year therapy revenue.

### AI-Enabled Histology and Risk Scoring

Machine-learning pathology scoring now reads fibrosis stage with 0.87 concordance against expert consensus, reducing central-read variability that historically inflated trial sample sizes by 20–30% [10]. PathAI and Histoindex platforms are embedded in at least eleven active Phase III programs. Beyond trials, algorithmic risk stratification applied to [electronic health records](https://www.marketresearchfuture.com/reports/electronic-health-records-market-66597) surfaces high-risk patients who never present to hepatology, converting silent prevalence into diagnosed demand.

## Restraints

## Restraints Impact Analysis

| Restraint | ~% Drag on CAGR | Geographic Relevance | Impact Timeline | Ref |
| --- | --- | --- | --- | --- |
| High therapy pricing and payer resistance | -2.4 | North America, Europe | Medium-term (2–4 yr) | [11] |
| Diagnostic underdetection in primary care | -1.9 | Global | Long-term (≥4 yr) | [12] |
| Clinical trial enrollment and endpoint difficulty | -1.6 | Global | Medium-term (2–4 yr) | [13] |
| Lifestyle intervention as first-line standard | -1.2 | Europe, Asia-Pacific | Short-term (≤2 yr) | [14] |
| Safety and tolerability discontinuation rates | -0.9 | Global | Short-term (≤2 yr) | [15] |

### High Therapy Pricing and Payer Resistance

Branded MASH therapy is more expensive than the majority of chronic metabolic drugs, with an annual U.S. list price close to USD 47,400 [11]. In response, commercial payers implemented step-edit requirements that require documented F2–F3 fibrosis, hence excluding a significant portion of individuals with diagnoses. The health-benefit price benchmark was significantly lower than the list price in ICER's 2024 assessment, which increased negotiating power and reduced realized net pricing.

### Diagnostic Underdetection in Primary Care

At any given time, an estimated 76% of patients with severe hepatic fibrosis go undetected [12]. Although a third of fibrotic patients have normal enzymes, primary-care doctors hardly ever conduct staging tests in the absence of aberrant transaminases. Referral bottlenecks exacerbate the disparity; in several European systems, median hepatology wait times surpass nine weeks, delaying the start of treatment well past the stage at which medication yields the greatest histological benefit.

### Clinical Trial Enrollment and Endpoint Difficulty

Screen-failure rates in biopsy-confirmed MASH trials routinely exceed 60%, driving per-patient enrollment costs above USD 90,000 [13]. Placebo response on histological endpoints has ranged from 12% to 25% across programs, inflating required sample sizes. Several late-stage assets missed primary endpoints despite favorable [biomarker](https://www.marketresearchfuture.com/reports/biomarker-market-1941) movement, and each failure raises the perceived development risk that sponsors price into portfolio decisions.

### Lifestyle Intervention as First-Line Standard

Guidelines still position 7–10% body-weight reduction as first-line management, and payers enforce it [14]. Documented lifestyle-intervention attempts of three to six months are required before pharmacotherapy authorization in many plans. Although long-term adherence sits below 20%, the requirement delays revenue recognition per patient and structurally caps near-term treated-population growth across both commercial and public systems.

### Safety and Tolerability Discontinuation Rates

Pruritus, LDL elevation, and gastrointestinal effects have driven discontinuation in 8–14% of treated patients across pivotal programs [15]. Obeticholic acid's regulatory setbacks illustrated how tolerability signals can override efficacy data. Persistent monitoring requirements — lipid panels, hepatic enzymes — add clinic burden that hepatology practices absorb reluctantly, slowing prescriber adoption outside academic centers.

## Opportunities

## Non Alcoholic Fatty Liver Disease Market Opportunities

### Combination Regimen Portfolios

Single-agent histological response ceilings near 30% leave substantial headroom for combination approaches pairing nuclear-receptor modulators with incretin analogs or anti-fibrotics. Early combination readouts suggest additive resolution rates approaching 45%. Sponsors holding two complementary mechanisms internally avoid the royalty stacking that bilateral licensing imposes, which is why pipeline breadth now commands acquisition premiums.

### Asia-Pacific Diagnosed-Population Expansion

China and India together carry an estimated 480 million adults with hepatic steatosis, yet treated penetration remains below 2%. India's Ayushman Bharat scheme extended hepatology coverage to 550 million beneficiaries, and China's NRDL added elastography reimbursement in 2024. Manufacturers pursuing volume-tiered pricing and local manufacturing partnerships can capture share ahead of Western pricing pressure reaching parity.

### Real-World Evidence and Registry Monetization

Longitudinal registries linking non-invasive staging to outcomes have become a tradeable asset. The Global NASH Registry now holds records for over 40,000 patients, and payers increasingly demand real-world durability data before renewing formulary placement. Diagnostic vendors and health systems that structure de-identified staging datasets can license them to sponsors for label expansion and post-marketing commitments, creating recurring revenue independent of device sales.

### Point-of-Care Screening in Endocrinology

Metabolic clinics see the highest-risk population daily but rarely stage the liver. Portable elastography units priced below USD 32,000 now fit endocrinology and bariatric practice economics, with reimbursement covering roughly USD 145 per scan. Embedding staging into routine diabetes review converts an existing patient flow into a diagnosed pipeline — the most capital-efficient patient-finding channel available.

### Pediatric and Adolescent Indications

Pediatric hepatic steatosis prevalence has reached 13% in adolescent obesity cohorts, yet no approved therapy carries a pediatric label. FDA's PREA requirements now trigger pediatric study plans for MASH assets, and sponsors completing them earn six months of exclusivity extension. Early movers face limited competition and a patient population with decades of treatment duration ahead.

## Future Outlook

## Non Alcoholic Fatty Liver Disease Market Future Outlook

### Combination Therapy Becomes Standard of Care

Monotherapy will look transitional by 2030. Ongoing trials pairing thyroid-hormone receptor agonists with incretin analogs target histological resolution above 50%, roughly double current single-agent performance. Regulators have signalled willingness to review fixed-dose combinations under existing surrogate frameworks, which compresses approval timelines. Expect the first combination approvals around 2029–2030, with combination regimens capturing an estimated 38% of therapy revenue by 2035 as fibrosis-stage patients migrate to higher-efficacy protocols.

### Screening Moves Upstream Into Primary Care

Diagnosis, not therapy, determines the ceiling. WHO's 2024 acceleration framework for liver health set national screening coverage targets, and roughly 22 countries have adopted FIB-4 within routine metabolic review [7]. As algorithmic risk scoring embeds into electronic health records, patient identification shifts from symptom-triggered referral to population screening. Diagnosed prevalence could triple by 2035 even where underlying disease prevalence grows modestly, which is the single largest swing factor in long-range forecasting.

### Pricing Compression and Outcomes-Based Contracting

Launch pricing will not hold through a crowded 2029–2032 approval calendar. Payers are already piloting outcomes-based agreements that tie rebates to documented fibrosis regression measured non-invasively at 24 months. Net-to-list ratios in U.S. hepatology are projected to fall from roughly 0.72 to 0.58 by 2032. Manufacturers will defend margin through duration rather than price — longer treated tenure, broader fibrosis-stage labels, and earlier initiation.

### Manufacturing and Supply Localization in Asia

Volume growth in Asia-Pacific cannot be served economically from Western plants. Chinese and Indian contract manufacturers have added an estimated USD 3.4 billion in metabolic-drug API and formulation capacity since 2023, much of it qualified to FDA and EMA standards. Tiered-pricing strategies backed by local production allow branded sponsors to compete against domestic generics without eroding reference prices in high-income markets — a structural requirement for capturing the region's growth.

## Segment Insights

## Non Alcoholic Fatty Liver Disease Market Segmentation

### By Drug Class

| Segment | Metric (2025 unless noted) | Primary Demand Driver |
| --- | --- | --- |
| Antioxidants | 30.4% share | Generic availability and physician familiarity |
| Lipid Lipid-Lowering Agents | USD 3.28 Billion | Cardiovascular risk reduction in metabolic patients |
| Fibrosis Treatment Agents | USD 14.86 Billion by 2035 | Advanced-stage histological endpoints |
| Thiazolidinedione | 11.7% share | Insulin sensitization in diabetic cohorts |
| FXR Receptor Agonists | 17.94% CAGR (2026–2035) | Nuclear-receptor disease modification |
| Biguanides | 8.3% share | Metabolic comorbidity management |
| Other Drug Classes | 9.1% share | Emerging FGF-21 and CCR2/5 mechanisms |

Antioxidants lead the Non-Alcoholic Fatty Liver Disease NAFLD Market on cost and safety history, but moderate efficacy caps their trajectory as targeted agents arrive. FXR receptor agonists grow fastest because nuclear-receptor modulation addresses lipid handling and fibrosis simultaneously — the mechanism resmetirom's approval validated. Fibrosis treatment agents command premium pricing where histological regression is documented, while thiazolidinedione uptake remains constrained by cardiovascular and bone-density safety perceptions among prescribers.

### By Distribution Channel

| Segment | Metric (2025 unless noted) | Primary Demand Driver |
| --- | --- | --- |
| Hospital Pharmacies | 50.8% share | Specialist initiation and lab monitoring |
| Retail Pharmacies | USD 4.09 Billion | Comorbidity prescription volume |
| Online Pharmacies | 17.83% CAGR (2026–2035) | Telemedicine follow-up and home delivery |
| Other Distribution Channels | 6.4% share | Clinic dispensing and specialty hubs |

Hospital pharmacies retain leadership across the Non-Alcoholic Fatty Liver Disease NAFLD Market because branded therapy initiation requires prior authorization, baseline staging, and lipid monitoring that integrated systems handle internally. Online pharmacies grow fastest as maintenance-phase patients shift to home delivery under telemedicine oversight. Retail pharmacies hold volume through metformin and statin comorbidity scripts but see limited branded share, since specialty-drug economics rarely route through general retail.

## Regional Market Share Analysis

## Regional Market Share Analysis

| Region | Metric (2025) | Primary Investment Themes |
| --- | --- | --- |
| North America | 41.6% share | Branded launch scale-up, specialty pharmacy networks |
| Europe | USD 4.92 Billion | Guideline-driven screening, HTA-negotiated access |
| Asia-Pacific | 18.02% CAGR (2026–2035) | Diagnosed-population expansion, local manufacturing |
| South America | 5.1% share | Public-system tender access, generic metabolic agents |
| Middle East & Africa | USD 0.67 Billion | Diabetes-linked screening programs, private hospital demand |
| Total | USD 18.62 Billion | — |

North America anchors the Non-Alcoholic Fatty Liver Disease NAFLD Market on launch infrastructure and pricing, while Asia-Pacific supplies the volume growth that will reshape the revenue mix by the mid-2030s.

### North America

| Country | Metric | Key Driver |
| --- | --- | --- |
| US | 86.4% of region | First-mover branded therapy reimbursement |
| Canada | USD 0.71 Billion | CADTH-negotiated hepatology access |
| Mexico | 15.9% CAGR | IMSS metabolic screening expansion |

The United States commercialized MASH therapy before any other market, and the resulting infrastructure is difficult to replicate. Roughly 1,400 specialty pharmacies now handle hepatology dispensing, and CMS coverage decisions in 2024 embedded elastography into diabetes management pathways [9]. Canada's access lags by 14–18 months on average due to sequential CADTH and pCPA review, while Mexico's growth reflects IMSS pilot programs pairing diabetes clinics with portable staging equipment rather than branded therapy volume.

### Europe

| Country | Metric | Key Driver |
| --- | --- | --- |
| Germany | 23.8% of region | G-BA benefit assessment and early access |
| UK | USD 0.86 Billion | NICE pathway integration, NHS screening pilots |
| France | 16.4% of region | HAS reimbursement for non-invasive staging |
| Italy | 12.1% of region | Regional hepatology network density |
| Spain | 9.7% of the region | High metabolic syndrome prevalence |
| Nordic Countries | 16.9% CAGR | Registry-linked outcomes research |
| Russia | USD 0.31 Billion | Domestic generic metabolic supply |
| Rest of Europe | 8.4% of region | Gradual guideline harmonization |

European access is governed less by approval than by health-technology assessment. EASL's 2024 clinical practice guidelines formalized FIB-4 as the primary-care entry point, and eight national systems funded it within standard metabolic panels [9]. Germany's AMNOG process permits first-year free pricing followed by rebate negotiation, which front-loads sponsor revenue relative to the UK, where NICE cost-effectiveness thresholds have forced confidential discount agreements before broad NHS availability.

### Asia-Pacific

| Country | Metric | Key Driver |
| --- | --- | --- |
| China | 34.6% of region | NRDL elastography coverage, urban obesity |
| India | 19.42% CAGR | Ayushman Bharat hepatology inclusion |
| Japan | USD 0.94 Billion | PMDA Sakigake designation route |
| South Korea | 11.3% of region | National health screening liver panels |
| ASEAN | 8.9% of region | Private hospital metabolic clinics |
| Rest of Asia-Pacific | USD 0.28 Billion | Emerging diagnostic infrastructure |

Asia-Pacific's advantage is epidemiological scale meeting newly funded diagnostics. China added elastography to NRDL coverage in 2024 and now performs an estimated 6.2 million scans annually. India's growth is the steepest globally, driven by Ayushman Bharat's extension of hepatology procedures to 550 million beneficiaries alongside a domestic generic industry capable of supplying metabolic agents at a fraction of Western pricing. Japan remains the region's highest-value market per patient given PMDA's expedited pathway and universal coverage.

### South America

| Country | Metric | Key Driver |
| --- | --- | --- |
| Brazil | 58.7% of region | SUS metabolic disease programs |
| Argentina | USD 0.16 Billion | Private insurance hepatology coverage |
| Rest of South America | 15.8% CAGR | Regional diagnostic capacity build-out |

Brazil dominates regional revenue through SUS tender purchasing, which favors established generics over branded therapy but delivers volume at scale. ANVISA approved resmetirom in late 2025 without immediate SUS listing, leaving branded access confined to private plans covering roughly 24% of the population. Argentina's market moves with currency stability and import licensing, making forecast confidence lower than elsewhere despite comparable underlying prevalence.

### Middle East & Africa

| Country | Metric | Key Driver |
| --- | --- | --- |
| Saudi Arabia | 31.2% of region | Vision 2030 chronic disease screening |
| UAE | USD 0.14 Billion | Private hospital metabolic programs |
| South Africa | 17.6% of region | NHI pilot hepatology inclusion |
| Egypt | 16.4% CAGR | National liver health program legacy |
| Rest of MEA | 11.9% of region | Gradual diagnostic access improvement |

Gulf states lead regional spending because diabetes prevalence exceeds 17% in Saudi Arabia and the UAE, while sovereign health budgets absorb high-cost therapy without HTA friction. Egypt applies infrastructure built for its hepatitis C elimination campaign — the world's largest — to metabolic liver screening, giving it unusual diagnostic reach for its income level. Sub-Saharan access remains constrained by hepatology workforce density below one specialist per million population.

## Competitive Benchmarking

## Competitive Benchmarking

Concentration is moderate and loosening. The estimated HHI sits near 1,180, with the top five participants holding roughly 46–52% of 2025 revenue. That structure reflects a market in transition: incumbent metabolic and hepatology franchises still carry substantial generic and adjacent-therapy revenue, while a first-mover branded entrant has captured disproportionate value from a single asset. As the 2029–2032 approval calendar delivers, share should fragment further — no participant currently holds a portfolio broad enough to dominate combination-era prescribing.

| Company | Est. Revenue Share Range | Key Offerings for Non-Alcoholic Fatty Liver Disease NAFLD Market | Strategic Positioning |
| --- | --- | --- | --- |
| Madrigal Pharmaceuticals | ~13–17% | Resmetirom (THR-β agonist) | First-mover branded franchise; single-asset concentration risk |
| Novo Nordisk | ~10–14% | Semaglutide MASH programs, GLP-1 portfolio | Metabolic scale advantage; injectable efficacy leadership |
| Eli Lilly | ~8–11% | Tirzepatide hepatic programs, incretin pipeline | Dual-agonist breadth; combination-ready portfolio |
| Intercept Pharmaceuticals | ~6–9% | Obeticholic acid, FXR platform | Deep FXR expertise; regulatory setback legacy |
| Gilead Sciences | ~5–8% | Anti-fibrotic candidates, hepatology franchise | Established liver-disease commercial infrastructure |
| Novartis | ~4–7% | FGF-21 and combination assets | Licensing-led entry; broad cardiometabolic reach |
| Boehringer Ingelheim | ~4–6% | Survodutide, metabolic pipeline | Dual-agonist differentiation in high-BMI cohorts |
| AstraZeneca | ~3–6% | Cotadutide, metabolic-renal portfolio | Cross-indication development efficiency |
| Bristol Myers Squibb | ~3–5% | FGF-21 analog programs | Fibrosis-focused mechanism bet |
| Viking Therapeutics | ~2–4% | VK2809 THR-β candidate | Late-stage challenger; acquisition candidate |
| Akero Therapeutics | ~2–4% | Efruxifermin FGF-21 analog | Cirrhotic-population differentiation |
| Sun Pharmaceutical | ~2–4% | Generic metabolic agents, emerging-market supply | Volume access play across Asia and MEA |

## Recent News & Developments

## Recent News & Developments

- U.S. Food and Drug Administration (March 2024): Granted accelerated approval to resmetirom for noncirrhotic MASH with moderate-to-advanced fibrosis, the first approved therapy for the indication and the event that created a branded revenue category [1]
- Novo Nordisk (June 2024): Reported 62.9% MASH resolution in the ESSENCE Phase III semaglutide trial, establishing injectable incretins as a credible competitive threat to oral monotherapy [16]
- European Medicines Agency (September 2024): Issued updated guidance accepting non-invasive fibrosis endpoints for conditional marketing authorization, shortening European development timelines [2]
- Roche (January 2024): Closed the USD 2.7 billion Carmot Therapeutics acquisition, citing hepatic and cardiometabolic endpoint potential across the acquired incretin portfolio [8]
- Centers for Medicare & Medicaid Services (July 2024): Extended national coverage for transient elastography within diabetes and obesity management pathways, expanding the reimbursed screening population [9]
- Madrigal Pharmaceuticals (February 2025): Announced European Commission conditional approval and initiated launches in Germany and Austria under AMNOG free-pricing provisions [17]
- Eli Lilly (April 2025): Reported Phase II SYNERGY-NASH data showing 74% MASH resolution at the highest tirzepatide dose, intensifying the combination-therapy race [18]
- National Institutes of Health (November 2023): Committed additional NIDDK funding toward the NASH Clinical Research Network, supporting biomarker validation across 12 academic centers [3]

## Report Scope

| Parameter | Detail |
| --- | --- |
| Market Scope | Global therapeutics and associated pharmacotherapy revenue for non-alcoholic fatty liver disease and steatohepatitis, segmented by drug class, distribution channel, and region |
| Study Period | 2021–2035 (Historical 2021–2024; Base Year 2025; Forecast 2026–2035) |
| CAGR | 16.75% (2026–2035) |
| Market Size Checkpoints | USD 18.62 Billion (2025); USD 21.74 Billion (2026); USD 87.94 Billion (2035) |
| Fastest Growing Segments | FXR Receptor Agonists (17.94% CAGR); Online Pharmacies (17.83% CAGR); Asia-Pacific (18.02% CAGR) |
| Companies Profiled | 12 participants including Madrigal Pharmaceuticals, Novo Nordisk, Eli Lilly, Intercept Pharmaceuticals, Gilead Sciences, Novartis, Boehringer Ingelheim, AstraZeneca, Bristol Myers Squibb, Viking Therapeutics, Akero Therapeutics, Sun Pharmaceutical |
| Valuation Currency | USD Billion, constant 2025 exchange rates |

## Frequently Asked Questions

**Q: What should investors evaluate before backing a single-asset participant in the Non-Alcoholic Fatty Liver Disease NAFLD Market?**
A: Portfolio breadth matters more than launch performance. Single-asset companies face acute risk when combination regimens become standard around 2030, since they must license a partner mechanism on unfavorable terms [8].

**Q: How do procurement teams evaluate non-invasive staging equipment for hospital purchase?**
A: Compare reimbursement per scan against throughput capacity, not unit price. Portable elastography units below USD 32,000 reach payback within 220 scans at typical U.S. rates [9]. Verify probe compatibility across BMI ranges before committing.

**Q: Which regulatory nuance most often delays European launch in the Non-Alcoholic Fatty Liver Disease NAFLD Market?**
A: Conditional marketing authorization requires confirmatory outcome data on a fixed timetable. Sponsors that under-resource the confirmatory trial risk withdrawal, and several national payers withhold listing until enrollment milestones are documented [2].

**Q: Is elastography or MRI-PDFF the better diagnostic investment for a mid-sized health system?**
A: Elastography wins on cost and throughput for population screening. MRI-PDFF delivers superior fat quantification but costs roughly eight times more per study and requires scanner time competing with oncology [12].

**Q: What integration challenge slows algorithmic risk scoring in the Non-Alcoholic Fatty Liver Disease NAFLD Market?**
A: Electronic health record interoperability. FIB-4 calculation needs platelet counts, transaminases, and age pulled from separate modules, and many legacy systems cannot automate that retrieval without custom middleware [10].

**Q: How are outcomes-based contracts structured for hepatology therapy?**
A: Rebates tie to documented fibrosis regression on non-invasive testing at 24 months. Manufacturers absorb a 15–30% clawback where thresholds are missed, which requires reliable longitudinal patient tracking [11].

**Q: Which emerging use case could expand the addressable population beyond hepatology?**
A: Cardiology referral pathways. Patients with hepatic fibrosis carry elevated cardiovascular mortality, and joint screening protocols in cardiometabolic clinics are entering pilot stages across several European systems [6].


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/non-alcoholic-fatty-liver-disease-market-42175*